株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Les Laboratoires Servier SAS:製品パイプライン分析

Les Laboratoires Servier SAS - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 253719
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.69円で換算しております。
Back to Top
Les Laboratoires Servier SAS:製品パイプライン分析 Les Laboratoires Servier SAS - Product Pipeline Review - 2016
出版日: 2016年03月31日 ページ情報: 英文 60 Pages
概要

Les Laboratoires Servier SASはフランスに本社を置く独立系で研究志向の製薬企業です。心血管系の疾患や中枢神経系疾患、糖尿病、癌、筋骨格および関節疾患の治療薬について、治療薬の研究開発、製造、販売を行っています。

当レポートでは、Les Laboratoires Servier SAS における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Les Laboratoires Servier SAS の基本情報

  • Les Laboratoires Servier SAS の概要
  • 主要情報
  • 企業情報

Les Laboratoires Servier SAS :R&Dの概要

  • 主な治療範囲

Les Laboratoires Servier SAS :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Les Laboratoires Servier SAS :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 申請登録前の製品/併用療法モダリティ
    • 第?相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第?相の製品/併用療法モダリティ
    • 第?相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

Les Laboratoires Servier SAS :薬剤プロファイル

  • (perindopril + amlodipine besylate)
  • gevokizumab
  • ivabradine
  • lucitanib
  • S-38844
  • S-47445
  • S-49076
  • S-055746
  • Small Molecule to Inhibit Mcl-1 for Cancer
  • Drugs to Inhibit Insulin-Regulated AminoPeptidase for Alzheimer's Disease
  • Monoclonal Antibodies for Cancer
  • Drugs for Breast Cancer

Les Laboratoires Servier SAS :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Les Laboratoires Servier SAS :最新のパイプライン情報

Les Laboratoires Servier SAS :開発休止中のプロジェクト

Les Laboratoires Servier SAS :開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル

Les Laboratoires Servier SAS :企業理念

Les Laboratoires Servier SAS :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

目次
Product Code: GMDHC08016CDB

Summary

Global Markets Direct's, 'Les Laboratoires Servier SAS - Product Pipeline Review - 2016', provides an overview of the Les Laboratoires Servier SAS's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Les Laboratoires Servier SAS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Les Laboratoires Servier SAS
  • The report provides overview of Les Laboratoires Servier SAS including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Les Laboratoires Servier SAS's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Les Laboratoires Servier SAS's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Les Laboratoires Servier SAS's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Les Laboratoires Servier SAS
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Les Laboratoires Servier SAS's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Bristol-Myers Squibb Company Snapshot
    • Bristol-Myers Squibb Company Overview
    • Key Information
    • Key Facts
  • Bristol-Myers Squibb Company - Research and Development Overview
    • Key Therapeutic Areas
  • Bristol-Myers Squibb Company - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Bristol-Myers Squibb Company - Pipeline Products Glance
  • Bristol-Myers Squibb Company - Late Stage Pipeline Products
  • Bristol-Myers Squibb Company - Clinical Stage Pipeline Products
  • Bristol-Myers Squibb Company - Early Stage Pipeline Products
  • Bristol-Myers Squibb Company - Drug Profiles
    • nivolumab
    • daclatasvir dihydrochloride + asunaprevir
    • abatacept
    • apixaban
    • beclabuvir hydrochloride
    • brivanib alaninate
    • ipilimumab
    • ulocuplumab
    • BMS-394136
    • BMS-754807
    • BMS-833923
    • BMS-919373
    • BMS-986020
    • BMS-986036
    • BMS-986142
    • CXL-1427
    • dasatinib
    • lirilumab
    • lulizumab pegol
    • Recombinant Protein to Antagonize Fibroblast Growth Factor Receptor for Fibrosis
    • urelumab
    • BMS-986004
    • BMS-986012
    • BMS-986016
    • BMS-986089
    • BMS-986148
    • BMS-986156
    • BMS-986158
    • TD-139
    • Antibody to Target CD40 Ligand for Immunology
    • Biologic to Inhibit PD-L1 for Immunology
    • BMS-262084
    • BMS-777607
    • BMS-813160
    • BMS-906024
    • BMS-963272
    • BMS-986090
    • BMS-986104
    • BMS-986115
    • BMS-986120
    • BMS-986141
    • BMS-986147
    • BMS-986165
    • BMS-986168
    • BMS-986171
    • BMS-986186
    • FLX-925
    • KOS-1803
    • Recombinant Protein 1 to Antagonize Fibroblast Growth Factor Receptor for Fibrosis
    • Small Molecule for Oncology
    • Small Molecule to Antagonize PAR4 for Thromboembolic Disorders
    • Small Molecule to Inhibit BTK for Immunology
    • Small Molecule to Inhibit MGAT2 for Type 2 Diabetes and Obesity
    • Small Molecule to Inhibit TYK2 for Immunology
    • BMS-817378
    • ALB-109780
    • AMR-2
    • ARX-720
    • BMS-457
    • BMS-593214
    • BMS-654457
    • BMS-751324
    • BMS-795311
    • BMS-816106
    • BMS-869780
    • BMS-871
    • BMS-884775
    • BMS-986177
    • BMS-986195
    • BMS-986205
    • CXL-1036
    • Drug for Metabolic Disorders
    • Drugs to Agonize FPR-2 for Inflammation
    • DT-1154
    • F-001287
    • NP-11948
    • Small Molecule 2 to Inhibit Factor XIa for Thrombosis
    • Small Molecule for Pulmonary Arterial Hypertension
    • Small Molecule to Activate Kv7.2 for Neuropathic Pain and Diabetic Neuropathy
    • Small Molecule to Antagonize Neuropeptide Y Receptor Y1 for Obesity
    • Small Molecule to Antagonize NK1R and Block SERT for Depression
    • Small Molecule to Inhibit IAP for Melanoma
    • Small Molecule to Inhibit NS5B for Hepatitis C
    • Small Molecule to Inhibit XIAP and c-IAP for Melanoma
    • Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease
    • Small Molecules to Inhibit ROR-Gamma for Inflammation
    • Monoclonal Antibody Conjugates for Oncology
    • Proteins for Immunology and Oncology
    • Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia
    • Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine
    • Small Molecules to Antagonize CCR2
    • Small Molecules to Inhibit IDO and TDO for Oncology
    • Small Molecules to Inhibit IDO for Oncology
    • Small Molecules to Inhibit JAK 3 for Inflammation and Autoimmune Diseases
    • Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders
    • Small Molecules to Inhibit TDO for Oncology
  • Bristol-Myers Squibb Company - Pipeline Analysis
    • Bristol-Myers Squibb Company - Pipeline Products by Target
    • Bristol-Myers Squibb Company - Pipeline Products by Route of Administration
    • Bristol-Myers Squibb Company - Pipeline Products by Molecule Type
    • Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action
  • Bristol-Myers Squibb Company - Recent Pipeline Updates
  • Bristol-Myers Squibb Company - Dormant Projects
  • Bristol-Myers Squibb Company - Dormant Projects
  • Bristol-Myers Squibb Company - Discontinued Pipeline Products
  • Bristol-Myers Squibb Company - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Bristol-Myers Squibb Company - Company Statement
  • Bristol-Myers Squibb Company - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Bristol-Myers Squibb Company - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Bristol-Myers Squibb Company, Key Information
  • Bristol-Myers Squibb Company, Key Facts
  • Bristol-Myers Squibb Company - Pipeline by Indication, 2016
  • Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016
  • Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016
  • Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Partnered Products/ Combination Treatment Modalities, 2016
  • Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Bristol-Myers Squibb Company - Pre-Registration, 2016
  • Bristol-Myers Squibb Company - Filing rejected/Withdrawn, 2016
  • Bristol-Myers Squibb Company - Phase III, 2016
  • Bristol-Myers Squibb Company - Phase II, 2016
  • Bristol-Myers Squibb Company - Phase I, 2016
  • Bristol-Myers Squibb Company - IND/CTA Filed, 2016
  • Bristol-Myers Squibb Company - Preclinical, 2016
  • Bristol-Myers Squibb Company - Discovery, 2016
  • Bristol-Myers Squibb Company - Pipeline by Target, 2016
  • Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016
  • Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016
  • Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action, 2016
  • Bristol-Myers Squibb Company - Recent Pipeline Updates, 2016
  • Bristol-Myers Squibb Company - Dormant Developmental Projects,2016
  • Bristol-Myers Squibb Company - Discontinued Pipeline Products, 2016
  • Bristol-Myers Squibb Company, Other Locations
  • Bristol-Myers Squibb Company, Subsidiaries
  • Bristol-Myers Squibb Company, Key Manufacturing Facilities

List of Figures

  • Bristol-Myers Squibb Company - Pipeline by Top 10 Indication, 2016
  • Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016
  • Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016
  • Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Pipeline by Top 10 Target, 2016
  • Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016
  • Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016
  • Bristol-Myers Squibb Company - Pipeline Products by Top 10 Mechanism of Action, 2016

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Bristol-Myers Squibb Company Snapshot
  • Bristol-Myers Squibb Company Overview
  • Key Information
  • Key Facts
  • Bristol-Myers Squibb Company - Research and Development Overview
  • Key Therapeutic Areas
  • Bristol-Myers Squibb Company - Pipeline Review
  • Pipeline Products by Stage of Development
  • Pipeline Products - Monotherapy
  • Pipeline Products - Combination Treatment Modalities
  • Pipeline Products - Partnered Products
  • Pipeline Products - Out-Licensed Products
  • Bristol-Myers Squibb Company - Pipeline Products Glance
  • Bristol-Myers Squibb Company - Late Stage Pipeline Products
  • Bristol-Myers Squibb Company - Clinical Stage Pipeline Products
  • Bristol-Myers Squibb Company - Early Stage Pipeline Products
  • Bristol-Myers Squibb Company - Drug Profiles
  • nivolumab
  • daclatasvir dihydrochloride + asunaprevir
  • abatacept
  • apixaban
  • beclabuvir hydrochloride
  • brivanib alaninate
  • ipilimumab
  • ulocuplumab
  • BMS-394136
  • BMS-754807
  • BMS-833923
  • BMS-919373
  • BMS-986020
  • BMS-986036
  • BMS-986142
  • CXL-1427
  • dasatinib
  • lirilumab
  • lulizumab pegol
  • Recombinant Protein to Antagonize Fibroblast Growth Factor Receptor for Fibrosis
  • urelumab
  • BMS-986004
  • BMS-986012
  • BMS-986016
  • BMS-986089
  • BMS-986148
  • BMS-986156
  • BMS-986158
  • TD-139
  • Antibody to Target CD40 Ligand for Immunology
  • Biologic to Inhibit PD-L1 for Immunology
  • BMS-262084
  • BMS-777607
  • BMS-813160
  • BMS-906024
  • BMS-963272
  • BMS-986090
  • BMS-986104
  • BMS-986115
  • BMS-986120
  • BMS-986141
  • BMS-986147
  • BMS-986165
  • BMS-986168
  • BMS-986171
  • BMS-986186
  • FLX-925
  • KOS-1803
  • Recombinant Protein 1 to Antagonize Fibroblast Growth Factor Receptor for Fibrosis
  • Small Molecule for Oncology
  • Small Molecule to Antagonize PAR4 for Thromboembolic Disorders
  • Small Molecule to Inhibit BTK for Immunology
  • Small Molecule to Inhibit MGAT2 for Type 2 Diabetes and Obesity
  • Small Molecule to Inhibit TYK2 for Immunology
  • BMS-817378
  • ALB-109780
  • AMR-2
  • ARX-720
  • BMS-457
  • BMS-593214
  • BMS-654457
  • BMS-751324
  • BMS-795311
  • BMS-816106
  • BMS-869780
  • BMS-871
  • BMS-884775
  • BMS-986177
  • BMS-986195
  • BMS-986205
  • CXL-1036
  • Drug for Metabolic Disorders
  • Drugs to Agonize FPR-2 for Inflammation
  • DT-1154
  • F-001287
  • NP-11948
  • Small Molecule 2 to Inhibit Factor XIa for Thrombosis
  • Small Molecule for Pulmonary Arterial Hypertension
  • Small Molecule to Activate Kv7.2 for Neuropathic Pain and Diabetic Neuropathy
  • Small Molecule to Antagonize Neuropeptide Y Receptor Y1 for Obesity
  • Small Molecule to Antagonize NK1R and Block SERT for Depression
  • Small Molecule to Inhibit IAP for Melanoma
  • Small Molecule to Inhibit NS5B for Hepatitis C
  • Small Molecule to Inhibit XIAP and c-IAP for Melanoma
  • Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease
  • Small Molecules to Inhibit ROR-Gamma for Inflammation
  • Monoclonal Antibody Conjugates for Oncology
  • Proteins for Immunology and Oncology
  • Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia
  • Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine
  • Small Molecules to Antagonize CCR2
  • Small Molecules to Inhibit IDO and TDO for Oncology
  • Small Molecules to Inhibit IDO for Oncology
  • Small Molecules to Inhibit JAK 3 for Inflammation and Autoimmune Diseases
  • Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders
  • Small Molecules to Inhibit TDO for Oncology
  • Bristol-Myers Squibb Company - Pipeline Analysis
  • Bristol-Myers Squibb Company - Pipeline Products by Target
  • Bristol-Myers Squibb Company - Pipeline Products by Route of Administration
  • Bristol-Myers Squibb Company - Pipeline Products by Molecule Type
  • Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action
  • Bristol-Myers Squibb Company - Recent Pipeline Updates
  • Bristol-Myers Squibb Company - Dormant Projects
  • Bristol-Myers Squibb Company - Dormant Projects
  • Bristol-Myers Squibb Company - Discontinued Pipeline Products
  • Bristol-Myers Squibb Company - Discontinued Pipeline Products
  • Discontinued Pipeline Product Profiles
  • Bristol-Myers Squibb Company - Company Statement
  • Bristol-Myers Squibb Company - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Bristol-Myers Squibb Company - Key Manufacturing Facilities
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Bristol-Myers Squibb Company, Key Information
  • Bristol-Myers Squibb Company, Key Facts
  • Bristol-Myers Squibb Company - Pipeline by Indication, 2016
  • Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016
  • Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016
  • Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Partnered Products/ Combination Treatment Modalities, 2016
  • Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Bristol-Myers Squibb Company - Pre-Registration, 2016
  • Bristol-Myers Squibb Company - Filing rejected/Withdrawn, 2016
  • Bristol-Myers Squibb Company - Phase III, 2016
  • Bristol-Myers Squibb Company - Phase II, 2016
  • Bristol-Myers Squibb Company - Phase I, 2016
  • Bristol-Myers Squibb Company - IND/CTA Filed, 2016
  • Bristol-Myers Squibb Company - Preclinical, 2016
  • Bristol-Myers Squibb Company - Discovery, 2016
  • Bristol-Myers Squibb Company - Pipeline by Target, 2016
  • Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016
  • Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016
  • Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action, 2016
  • Bristol-Myers Squibb Company - Recent Pipeline Updates, 2016
  • Bristol-Myers Squibb Company - Dormant Developmental Projects,2016
  • Bristol-Myers Squibb Company - Discontinued Pipeline Products, 2016
  • Bristol-Myers Squibb Company, Other Locations
  • Bristol-Myers Squibb Company, Subsidiaries
  • Bristol-Myers Squibb Company, Key Manufacturing Facilities

List of Figures

  • Bristol-Myers Squibb Company - Pipeline by Top 10 Indication, 2016
  • Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016
  • Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016
  • Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Pipeline by Top 10 Target, 2016
  • Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016
  • Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016
  • Bristol-Myers Squibb Company - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top